최소 단어 이상 선택하여야 합니다.
최대 10 단어까지만 선택 가능합니다.
다음과 같은 기능을 한번의 로그인으로 사용 할 수 있습니다.
NTIS 바로가기Bioorganic & medicinal chemistry letters, v.10 no.24, 2000년, pp.2787 - 2790
Tsubaki, Kazunori (Medicinal Chemistry Research Laboratories, Fujisawa Pharmaceutical Co., Ltd, 1-6, 2-Chome, Kashima, Yodogawa-ku, Osaka 532-8514, Japan) , Taniguchi, Kiyoshi (Medicinal Chemistry Research Laboratories, Fujisawa Pharmaceutical Co., Ltd, 1-6, 2-Chome, Kashima, Yodogawa-ku, Osaka 532-8514, Japan) , Tabuchi, Seiichiro (Medicinal Chemistry Research Laboratories, Fujisawa Pharmaceutical Co., Ltd, 1-6, 2-Chome, Kashima, Yodogawa-ku, Osaka 532-8514, Japan) , Okitsu, Osamu (Medicinal Chemistry Research Laboratories, Fujisawa Pharmaceutical Co., Ltd, 1-6, 2-Chome, Kashima, Yodogawa-ku, Osaka 532-8514, Japan) , Hattori, Kouji (Medicinal Chemistry Research Laboratories, Fujisawa Pharmaceutical Co., Ltd, 1-6, 2-Chome, Kashima, Yodogawa-ku, Osaka 532-8514, Japan) , Seki, Jiro (Medicinal Biology Research Laboratories, Fujisawa Pharmaceutical Co., Ltd, 1-6, 2-Chome, Kashima, Yodogawa-ku, Osaka 532-8514, Japan) , Sakane, Kazuo (Medicinal Chemistry Research Laboratories, Fujisawa Pharmaceutical Co., Ltd, 1-6, 2-Chome, Kashima, Yodogawa-ku, Osaka 532-8514, Japan) , Tanaka, Hirokazu (Medicinal Chemistry Research Laboratories,)
AbstractA novel optically pure pyridazinone derivative was synthesized and identified as a nonprostanoid PGI2 agonist. It inhibited ADP-induced aggregation of human platelets with an IC50 value of 0.081μM and has high oral bioavailability (56%) with a long half-life (4.3h) in rats....
10.1038/263663a0 (a) Moncada, S.; Gryglewski, R.; Bunting, S.; Vane, J. R. Nature 1976, 263, 663.
10.1358/dof.1994.019.04.595583 (b) Meanwell, N. A.; Romine, J. L.; Seiler, S. M. Drugs Future 1994, 19, 361.
10.1021/cr00020a007 (c) Collins, P. W.; Djuric, S. W. Chem. Rev. 1993, 93, 1533.
10.3999/jscpt.20.515 (a) Kato, R.; Uji, Y.; Matsumoto, K. Jpn. J. Clin. Pharmacol. Ther. 1989, 20, 515.
(b) Matsumoto, K.; Tajima, A.; Hirano, Y.; Ohno, K.; Yuge, T.; Hamasaki, T.; Hase, T.; Horiba, M. Xenobio. Metabol. Dispos. 1989, 4, 713.
10.3999/jscpt.20.529 (d) Kato, R.; Uji, Y.; Matsumoto, K. Jpn. J. Clin. Pharmacol. Ther. 1989, 20, 529.
10.1055/s-0038-1648149 (e) Isaka, Y.; Handa, N.; Imaizumi, M.; Kimura, K.; Kamada, T. Thromb. Haemost. 1991, 65, 344.
(a) Seiler, S. M.; Brassard, C. L.; Arnold, A. J.; Meanwell, N. A.; Fleming, J. S.; Keely, S. L., Jr. J. Pharm. Exp. Ther. 1990, 255, 1021.
10.1111/j.1476-5381.1991.tb12162.x (b) Merritt, J. E.; Hallam, T. J.; Brown, A. M.; Boyfield, I.; Cooper, D. G.; Hickey, D. M. B.; Jaxa-Chamiec, A. A.; Kaumann, A. J.; Keen, M.; Kelly, E.; Kozlowski, U.; Lynham, J. A.; Moores, K. E.; Murray, K. J.; MacDermot, J.; Rink, T. J. Brit. J. Pharmacol. 1991, 102, 251.
10.1021/jm00080a028 (c) Meanwell, N. A.; Rosenfeld, M. J.; Kim Wright J. J.; Brassard, C. L.; Buchanan, J. O.; Federici, M. E.; Fleming, J. S.; Seiler, S. M. J. Med. Chem. 1992, 35, 389.
10.1021/jm00076a018 (d) Meanwell, N. A.; Romine, J. L.; Rosenfeld, M. J.; Martin, S. W.; Trehan, A. K.; Kim Wright, J. J.; Malley, M. F.; Gougoutas, J. Z.; Brassard, C. L.; Buchanan, J. O.; Federici, M. E.; Fleming, J. S.; Gamberdella, M.; Hartl, K. S.; Zavoico, G. B.; Seiler, S. M. J. Med. Chem. 1993, 36, 3884.
10.1254/fpj.106.181 (a) Kondo, K.; Hamanaka, N. Folia Pharmacol. Jpn. 1995, 106, 181.
10.1016/0960-894X(95)00168-S (b) Hamanaka, N.; Takahashi, K.; Nagao, Y.; Torisu, K.; Takada, H.; Tokumoto, H.; Kondo, K. Bioorg. Med. Chem. Lett. 1995, 5, 1071.
10.1016/0960-894X(95)00170-X (c) Hamanaka, N.; Takahashi, K.; Nagao, Y.; Torisu, K.; Tokumoto, H.; Kondo, K. Bioorg. Med. Chem. Lett. 1995, 5, 1083.
10.1016/0960-894X(95)00169-T (d) Hamanaka, N.; Takahashi, K.; Nagao, Y.; Torisu, K.; Tokumoto, H.; Kondo, K. Bioorg. Med. Chem. Lett. 1995, 5, 1077.
10.3987/COM-95-S97 (e) Nagao, Y.; Takahashi, K.; Torisu, K.; Kondo, K.; Hamanaka, N. Heterocycles 1996, 42, 517.
Tetrahedron Lett. Genet 35 4559 1994 10.1016/S0040-4039(00)60727-X
Physical data for compound FR181877 (4): mp 82-83°C (AcOEt); [α]D25 ?27.6° (c 0.75, CH2Cl2); IR (Nujol) cm?1: 1730, 1655, 1635, 1565; 1H NMR (DMSO-d6) δ: 1.34 (1H, m), 1.77 (1H, m), 2.20 (1H, m), 2.35-2.85 (4H, m), 3.90-4.10 (2H, m), 4.65 (2H, s), 5.57 (1H, s), 6.56-6.62 (2H, m), 6.92 (1H, d, J=9.5Hz), 7.01 (1H, t, J=7.9Hz), 7.20-7.37 (11H, m), 12.94 (1H, br s); (+)APCI-MS m/z: 481 (M++1).
Soul Taehakkyo Yakhak Nonmunjip Cook 8 1 1983
Sherlock, M. H.; Roebke, H. US Patent 4,138,488, 1979; Chem. Abstr. 1979, 90, 168465n.
Physical data for compound 29: mp 185-187°C (Et2O); IR (Nujol) cm?1: 1730, 1645, 1590, 1560; 1H NMR (DMSO-d6) δ: 1.35 (1H, m), 1.80 (1H, m), 2.15 (1H, m), 2.35-2.95 (4H, m), 3.89 (2H, m), 4.30 (2H, s), 5.64 (1H, s), 6.20 (1H, t, J=6.7Hz), 6.54 (2H, d, J=7.9Hz), 6.85 (1H, d, J=6.7Hz), 6.95 (1H, t, J=7.9Hz), 7.05-7.30 (10H, m), 7.62 (1H, d, J=6.7Hz); (+)APCI-MS m/z: 480 (M++1).
Physical data for compound 30: mp 162-163°C (Et2O); IR (Nujol) cm?1: 1665, 1605, 1590; 1H NMR (DMSO-d6) δ: 1.30 (1H, m), 1.80 (1H, m), 2.10 (1H, m), 2.35-2.95 (4H, m), 3.70-3.95 (2H, m), 4.28 (2H, s), 5.39 (1H, s), 6.39 (1H, d, J=10.1Hz), 6.48-6.56 (2H, m), 6.95 (1H, t, J=7.9Hz), 7.14-7.35 (12H, m); (+)APCI-MS m/z: 480 (M++1).
*원문 PDF 파일 및 링크정보가 존재하지 않을 경우 KISTI DDS 시스템에서 제공하는 원문복사서비스를 사용할 수 있습니다.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.